Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Middle East Conflict Impacts Australia and New Zealand Businesses 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
(4) - EconoTimes)
BURLINGTON, Mass., May 03, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to seven new employees for an aggregate of 38,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of May 1, 2018. The stock options have an exercise price of $25.22 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a stock option agreement pursuant to which the stock option was granted.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Corporate Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
